Under CEO Robert Bradway, Amgen made an Asian expansion one of its top priorities this year, and it's followed through with a decision to set up a new research center in Shanghai.
As third-quarter earnings season nears, analysts are totting up the potential losses in China. And for GlaxoSmithKline, at the heart of the pharma bribery scandal there, the damage to sales may run up to 30%.
Sanofi has decided it is worth building manufacturing capacity in Vietnam, a country with tremendous growth potential. But for all that upside, it is a market with big challenges when it comes to drug production.
South Africa has a well-established pharmaceutical industry, and North Africa is attracting more attention from Western drugmakers. But many countries in between have limited infrastructure or challenging political situations. Figuring out which have the potential to be emerging markets worth investing in can be a challenge. Jordan-based Hikma sees potential in Ethiopia.
There's no doubt the pharma bribery scandal has been bad for business in China. Just how bad? That remains to be seen. But in the meantime, Reuters reports that drugmakers are struggling to push their products--and explores how those problems might affect third-quarter results.
Hikma, which already has a strong foothold in North Africa, intends to invest deeper there. The Jordan-based company has created a joint venture in Ethiopia that will build a manufacturing plant.
The bribery allegations in China just keep on coming. Novartis' Alcon eyecare division now says it will investigate claims it used fabricated clinical trials to bribe doctors. The news is none too welcome for Novartis, which has already faced a set of bribery accusations in China.
Boston Scientific unveiled separate training and innovation centers in China this week, underscoring its focus on the surging country as a key part of its rehabilitation and renewed growth.
Add Bayer to the list of companies Chinese authorities are investigating. Friday, a Bayer spokeswoman told The Wall Street Journal China's probe has reached the German pharma for a "potential case of unfair competition" as the country's government continues its industry-wide crackdown.
A key element of a plan by KKR to invest in India's Gland Pharma is to boost its manufacturing capacity, and so significantly increase its earnings potential.